Are There Scientific Evidences that the Stem Cell Use Is Benefic to Patient with Dilated Cardiomyopathy?
The dilated cardiomyopathy (DCM) is one of the most important causes of cardiac insufficiency, leading to morbidity and mortality augment, due to therapeutic restriction. Objective: To search scientific evidences about the treatment of dilated cardiomyopathy with stem cells use. Results: The stem cells use in this pathology has shown benefits through human and animals experiments, verified through images and laboratorial exams. Conclusion: Even with positive results, this treatment requires deeper studies that can show consistent vantages of this therapy in humans.
Joanne P, Kitsara M, Boitard SE et al. Nanoﬁbrous clinical-grade collagen scaffolds seeded with human cardiomyocytes induces cardiac remodeling in dilated cardiomyopathy. Biomaterials. 2015; 80 : 157-168.
Nagaya N., Kangawa K., Itoh T., Iwase T., Murakami S., Miyahara Y., Fujii T., Uematsu M., Ohgushi H., Yamagishi M., et al., 2005. Transplantation of mesenchymal stem cells improves cardiac function in a rat model of dilated cardiomyopathy. Circulation 112, 1128–1135.
Morschbacher P.D., Garcez T.N.A. , Paz A.H., Magrisso A.B., Mello H.F., Rolim V.M., Neuwald E.B., Driemeier D., Contesini E.A., Cirne-Lima E. Treatment of dilated cardiomyopathy in rabbits with mesenchymal stem cell transplantation and platelet-rich plasma. Journal The Veterinary Journal 209 (2016) 180–185
Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. American College of Cardiology Foundation, American Heart Association. 2009 focused update incorporated into the acc/aha 2005 guidelines for the diagnosis and management of heart failure in adults a report of the American College of Cardiology
Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the international society for heart and lung transplantation. J Am Coll Cardiol 2009; 53:e1e90.
Hadad F, Sever M, Poglajen G, Lezaic L, Yang P, Maecker H, et al. Immunologic Network and Response to Intramyocardial CD34D Stem Cell Therapy in Patients With Dilated Cardiomyopathy. J of Cardiac Failure 2015; 21: 572-582
Kelkar AA, Butler J, Schelbert EB, Greene SJ, Quyyumi AA, Bonow RO, et al. Mechanisms Contributing to the Progression of Ischemic and Nonischemic Dilated Cardiomyopathy Possible Modulating Effects of Paracrine Activities of Stem Cells. J Am Coll Cardiol 2015;66:2038–47
Garzón F. B., Romero M., Lezo J.S., Pineda S.O., Herrera C., Lezo J.S. Miocardiopatia dilatada idiopática tratada con infusion intracoronaria de células autólogas de medula óssea: seguimiento a largo plazo. Cartas científicas / Rev Esp Cardiol. 2015;68(8):719–730726.
Gong X, Wang P, Wu Q, Wang S, Yu L, Wang G. Humam umbilical cord blood derived mesenchymal stem cells improve cardic function in cTnTR141W transgenic mouse of dilated cardiomyopathy. Europen Journal of Cell Bilogic 2015;
Gnecchi M, Zhang Z, Ni A, et al. Paracrine mechanisms in adult stem cell signaling and
therapy. Circ Res 2008;103:1204–19.
Jin, H.J., Bae, Y.K., Kim, M., Kwon, S.J., Jeon, H.B., Choi, S.J., Kim, S.W., Yang,Y.S., Oh,W., Chang, J.W., 2013. Comparative analysis of human mesenchymal stem cells from bone marrow, adipose tissue, and umbilical cord blood as sources of cell therapy. Int. J. Mol. Sci. 14, 17986–18001.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright policies & self-archiving
We are a RoMEO green journal.
Author's Pre-print: author can archive pre-print (ie pre-refereeing)
Author's Post-print: author can archive post-print (ie final draft post-refereeing)
Publisher's Version/PDF: author can archive publisher's version/PDF
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access and Benefits of Publishing Open Access).
This journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge.
Articles are published Under License of Creative Commons Attribution 4.0 License ©